<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673270</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2007-0077969-20</org_study_id>
    <secondary_id>CIC0203/029</secondary_id>
    <nct_id>NCT00673270</nct_id>
  </id_info>
  <brief_title>Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression</brief_title>
  <acronym>AFLUCO2</acronym>
  <official_title>Hemodynamic and Biological Effects of Fludrocortisone and Hydrocortisone, in Healthy Volunteers With Aldosterone Induced Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock (associated with relative adrenal insufficiency) is characterized by decreased
      arterial responsiveness to catecholamines. The association of hydrocortisone and
      fludrocortisone has demonstrated an improvement in survival in septic shock patients. If
      hydrocortisone has shown to increase vascular responsiveness, the role of fludrocortisone
      remains to be elucidated. The purpose of our study is to investigate the effect of a
      physiological dose of fludrocortisone and/or hydrocortisone on phenylephrine-mean arterial
      pressure dose-response relationship in healthy volunteers with aldosterone suppression
      induced by intravenous sodium loading.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phenylephrine-mean arterial pressure dose-response relationship</measure>
    <time_frame>Between 1.5 and 3 hours after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic arterial pressures, heart rate, cardiac output, systemic vascular resistances</measure>
    <time_frame>Between administration time and 24 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic pressures, Augmentation Index (Aix)</measure>
    <time_frame>Between administration time and 12 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness: Carotid-femoral Pulse Wave Velocity</measure>
    <time_frame>Between administration time and 12 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humeral diameter and distensibility</measure>
    <time_frame>Between administration time and 12 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma electrolytes, blood glucose, serum creatinine</measure>
    <time_frame>Between administration time and 24 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin, aldosterone, norepinephrine, epinephrine, hydrocortisone, fludrocortisone concentrations</measure>
    <time_frame>Between administration time and 24 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary electrolytes excretion</measure>
    <time_frame>Between administration time and 24 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Renin Angiotensin</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludrocortisone and Hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludrocortisone and placebo of Hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo of Fludrocortisone and Hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Fludrocortisone and placebo of Hydrocortisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>50 µg of fludrocortisone per os</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>50 mg of intravenous hydrocortisone</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Fludrocortisone</intervention_name>
    <description>Tablet of placebo of Fludrocortisone</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Hydrocortisone</intervention_name>
    <description>2 ml of isotonic saline solution</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men between 20 and 30 years

          -  Body Mass Index between 18 kg/m² and 25 kg/m²

          -  Normal clinical examination

          -  Normal biological variables

          -  Normal electrocardiogram and echocardiography

          -  Written, voluntary informed consent

          -  Non smoker since at least a year

        Non-inclusion Criteria:

          -  Any history of significant allergy

          -  Subjects with abnormal renal, pulmonary, cardiovascular, endocrine or hepatic function

          -  Medication during the study

          -  Alcohol consumption more than 30g/day or drug addiction

          -  Positive serology for hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV.

          -  Exclusion period mentioned on the Healthy Volunteers National list

          -  Persons deprived of freedom or under guardianship
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno LAVIOLLE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BELLISSANT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité d'Investigation Clinique - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

